Company Overview and News

11
Simple Green, Midstream Red

20h seekingalpha
Midstream sold off along with most things this week, but as a whole did slightly better than the broad stock market, outperforming for a second straight week. MLPs were the best-performing group in midstream, benefiting from their renewed obscurity more than a flight to safety. Just like when the S&P 500 is going up, the market seems pre-occupied with itself, rather than paying much attention to midstream and certainly not MLPs.
KEYUF GPRE COG AR NAP AM GNE NNA KMI WMB GPP GNE AMGP KMR PBA FGP CVB KMRFZ GEL

8
Ferrellgas Acquires Two Blue Rhino Third-Party Distributors

2018-10-12 zacks
Ferrellgas Partners L.P. (FGP - Free Report) announced the buyout of Harvey, LA-based Salathe Gas Co and Walton, IN-based North Star Exchange Inc, which are third-party distributors for Ferrellgas’ Blue Rhino barbecue tank exchange division. The acquisitions are expectedto boost the company’s EBITDA in the propane tank exchange business.
CBSH CBSHP CVX WGP FGP CBCB

8
Ferrellgas Partners, L.P. Announces Acquisitions of Salathe Propane and North Star Exchange

2018-10-11 globenewswire
LIBERTY, Mo., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Ferrellgas Partners, L.P. (NYSE:FGP) (“Ferrellgas” or the “Company”) today announced it has completed the acquisitions of Salathe Gas Co. of Harvey, Louisiana, and North Star Exchange Inc. of Walton, Indiana. Both companies had been longtime third-party distributors for Ferrellgas’ Blue Rhino barbecue tank exchange division. The transactions are expected to be immediately accretive.
FGP

8
Implied Volatility Surging for Ferrellgas Partners (FGP) Stock Options

2018-10-08 zacks
Investors in Ferrellgas Partners, L.P. (FGP - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Feb 15, 2019 $2.50 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
FGP

26
80 Top 10%+ Yield WallStars For October 2019 From Dividend Dogcatcher

2018-10-05 seekingalpha - 2
WallStars have positive broker target price upsides. 80 stocks displayed 10%+ forward yield, $2.00+ prices, and $50M+ market caps as of 10/2/18. Yields above 12.4% narrowed the list to 30.
GOV AMID GARS AIC MMLP GOVNI NAP PER HCLP CCLP AI MDLY AIW FGP USDP CBL SNMP

11
New Strong Sell Stocks for October 4th

2018-10-04 zacks - 1
Capstone Turbine Corporation (CPST - Free Report) is the developer and manufacturer of microturbine technology solutions for use in stationary distributed power generation applications. The Zacks Consensus Estimate for its current year earnings has been revised more than 100% downward over the last 60 days.
BCH CSBR CPST FGP DLPH

9
FerrellGas Partners: Nails In The Coffin

2018-10-01 seekingalpha - 1
With the market cap where it is, raising equity is out of the equation. Bonds continue to trade at a discount to par.
APU FGP

11
Week Thoughts: Update From Zombieland

2018-10-01 seekingalpha
As if stuck on repeat, oil and natural gas were up, midstream was down this week. The S&P 500 paused its upward trajectory, and utilities were negative for a second straight week. Income securities had a rough month generally, and it feels like midstream is being painted with the "income stock" brush rather than the "energy stock" brush.
BKEP TGE AMID PAGP WGP SEP ANDX AM EQM NBLX EQGP OKE EEP FGP MPLX TLP ENLK GLNG SE ETP TCP GMLP DM WES SEMG

14
Ferrellgas Partners (FGP) Posts Wider-Than-Expected Q4 Loss

2018-09-28 zacks
Ferrellgas Partners LP (FGP - Free Report) reported fourth-quarter fiscal 2018 adjusted loss of 63 cents per unit, wider than the Zacks Consensus Estimate loss of 41 cents.
CLMT GPN SUN TRGP FGP

9
Ferrellgas Partners, L.P. (FGP) CEO James Ferrell on Q4 2018 Results - Earnings Call Transcript

2018-09-27 seekingalpha - 1
Good morning. My name is Kelly and I will be your conference operator today. At this time, I would like to welcome everyone to the Fourth Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you.
FGP

8
FGP / Ferrellgas Partners, L.P. 10-K (Annual Report)

2018-09-27 sec.gov
Document Table of Contents UNITED STATES
FGP

8
FGP / Ferrellgas Partners, L.P. 10-K (Annual Report)

2018-09-27 sec.gov
Document Table of Contents UNITED STATES
FGP

8
FGP / Ferrellgas Partners, L.P. 10-K (Annual Report)

2018-09-27 sec.gov
Document Table of Contents UNITED STATES
FGP

8
FGP / Ferrellgas Partners, L.P. 10-K (Annual Report)

2018-09-27 sec.gov
Document Table of Contents UNITED STATES
FGP

8
FGP / Ferrellgas Partners, L.P. 8-K (Current Report)

2018-09-27 sec.gov
UNITED STATES SECURIT
FGP

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

CUSIP: 315293100